<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03239652</url>
  </required_header>
  <id_info>
    <org_study_id>A-BR-105-055</org_study_id>
    <nct_id>NCT03239652</nct_id>
  </id_info>
  <brief_title>Taiwan ACE Beads for Embolization Therapy in Symptomatic Benign Prostatic Hyperplasia</brief_title>
  <official_title>Safety and Efficacy of Prostatic Artery Embolization Therapy in Symptomatic Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Industrial Technology Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cheng Kung University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Research Program for Biopharmaceuticals, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cheng-Kung University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this proposal, the investigators plan to conduct a clinical trial to validate the efficacy
      and safety of microspheres (T-ACE Beads).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      T-ACE Beads can be used for prostatic arterial embolization safely and efficiently.
      Furthermore, investigator's microspheres has advantageous characteristics in
      biodegradability, drug delivery capability, and cost-effectiveness. After the clinical trial,
      we anticipate introducing a new microsphere for Lower Urinary Tract Symptom/Benign prostatic
      hyperplasia patients, which is beneficial to the participants in precise medicine as well as
      in the pharmaceutical and medical device industry.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients Survival (Safety)</measure>
    <time_frame>An average of 12 weeks.</time_frame>
    <description>Survival rate was evaluated since treatment day until the date of death or final observation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change on Patient's Symptoms</measure>
    <time_frame>Before treatment, one and three months after treatment</time_frame>
    <description>Change on patients' International Prostate Symptom Score (IPSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on Prostate Volume</measure>
    <time_frame>Before treatment, one and three months after treatment.</time_frame>
    <description>Prostate volume measured using MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum Prostate Specific Antigen (PSA) concentration</measure>
    <time_frame>Before treatment, one and three months after treatment.</time_frame>
    <description>Measurement of Prostate Specific Antigen in patients undergoing this treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Lower Urinary Tract Symptom</condition>
  <condition>Benign Prostatic Hyperplasia (BPH)</condition>
  <arm_group>
    <arm_group_label>Taiwan ACE Beads microspheres</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The maximum use of dosage will not exceed 100 milligrams. The embolization procedure usually lasts less than an hour.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Taiwan ACE Beads</intervention_name>
    <description>Similar with conventional Transcatheter Arterial chemo-embolization, radiologist use Taiwan ACE Beads instead of Gelfoam or polyvinyl alcohol.</description>
    <arm_group_label>Taiwan ACE Beads microspheres</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        A. Men ≥ 50 years of age. Healthy patients or volunteers without diagnosis of Lower urinary
        tract symptoms (LUTS) / Benign prostatic hyperplasia (BPH) will not be included.

        B. Patients diagnosed of LUTS / BPH，International Prostate Symptom Score &gt; 12 with mild to
        severe symptom of LUTS.

        C. Prostate volume &gt; 50 mL.

        D. Urinary flow rate &lt;15 mL / sec.

        E. Ineffectiveness after 6 months of previous medical treatment, or the side effects are
        too difficult to tolerate.

        Exclusion Criteria:

        If patients meet any of the following criteria they may not be entered into the study:

        A. Major pelvic disease, or other malignancies.

        B. Prostate specific antigen of serum &gt; 10 ng/mL, malignant tumor not yet rule out
        (prostate specific antigen PSA&gt;10 ng/mL).

        C. Had Prostate surgery.

        D. Chronic bacterial prostatitis.

        E. Renal dysfunction or bladder diverticulum stones caused by prostate disease obstruction.

        F. Main organs (heart, lung, liver, kidney) dysfunction who are not eligible for clinical
        trials under physicians' consideration.

        G. White Blood Cell&lt; 2000 or Severe thrombocytopenia（Platelet count ＜50,000/μL)，or blood
        coagulation abnormalities uncorrectable .

        H. Unable to follow-up by MRI 3 times.

        I. Unable to follow-up by ultrasound or CT scan.

        J. Unwilling to sign a written informed consent form.

        K. Allergic to Iodine or other injections.

        L. Acute bacterial prostatitis.

        M. Patients with active urinary tract infections or recurrent urinary tract infections
        (&gt;2/years), prostatitis, or interstitial cystitis.

        N. Cases of biopsy proven prostate, bladder, or urethral cancer.

        O. Patients with glomerular filtration rates less than 40 who are not already on dialysis.

        P. Patients with bilateral internal iliac arterial occlusion.

        Q. Patients with causes of bladder obstruction not due to BPH (eg urethral stricture,
        bladder neck contraction, etc).

        R. Patients with neurogenic or bladder atonia.

        S. Patients where embolization is not possible distal to collateral vessels feeding
        non-prostatic tissue.

        T. Patients with major neurologic illnesses which could have symptoms that may be similar
        to or confused for BPH (eg multiple sclerosis, Shy-Drager syndrome, spinal cord injury,
        etc.).

        U. Patients with urethral stents.

        V. Other than hemorrhoidectomy or pelvic irradiation, patients who have undergone prior
        rectal surgery.

        W. Patients who have started or changed their dosage of alpha blockers or 5-alpha reductase
        inhibitors in the month prior to prostatic artery embolization.

        X. Allergic to pharmaceutical excipients related to Microspheres.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuh-Shyan Tsai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Urology, National Cheng Kung University Hospital, College of medicine, National Cheng Kung University, Tainan 70403, Taiwan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xi-Zhang Lin, MD</last_name>
    <phone>886-6-2353535</phone>
    <phone_ext>6202/3624</phone_ext>
    <email>linxz@mail.ncku.edu.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hui-Yu Hung, Bachelor</last_name>
    <phone>886-6-2353535</phone>
    <phone_ext>6202/3624</phone_ext>
    <email>z9908033@email.ncku.edu.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xi-Zhang Lin, MD</last_name>
      <phone>886-6-2353535</phone>
      <phone_ext>3624</phone_ext>
      <email>linxz@mail.ncku.edu.tw</email>
    </contact>
    <contact_backup>
      <last_name>Hui-Yu Hung, Bachelor</last_name>
      <phone>886-6-2353535</phone>
      <phone_ext>3624</phone_ext>
      <email>z9908033@email.ncku.edu.tw</email>
    </contact_backup>
    <investigator>
      <last_name>Yuh-Shyan Tsai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <results_reference>
    <citation>Liu YS, Lin XZ, Tsai HM, Tsai HW, Chen GC, Chen SF, Kang JW, Chou CM, Chen CY. Development of biodegradable radiopaque microsphere for arterial embolization-a pig study. World J Radiol. 2015 Aug 28;7(8):212-9. doi: 10.4329/wjr.v7.i8.212.</citation>
    <PMID>26339465</PMID>
  </results_reference>
  <results_reference>
    <citation>Noor A, Fischman AM. Prostate Artery Embolization as a New Treatment for Benign Prostate Hyperplasia: Contemporary Status in 2016. Curr Urol Rep. 2016 Jul;17(7):51. doi: 10.1007/s11934-016-0608-0. Review.</citation>
    <PMID>27146488</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2017</study_first_submitted>
  <study_first_submitted_qc>August 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2017</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microsphere</keyword>
  <keyword>Transcatheter Arterial chemo-embolization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

